SureNano Science Ltd. announced on November 19, 2025, that it has entered into a non-binding letter of intent with GlucaPharm Inc. to potentially acquire the privately held company and its exclusive licensing rights to Syracuse University's GEP-44 GLP-1 pharmaceutical compound technology. The proposed transaction represents a strategic move into the rapidly expanding GLP-1 therapeutics market, targeting improved patient tolerability and administration methods.
Novel GLP-1 Compound Targets Administration and Tolerability Challenges
GlucaPharm holds exclusive rights to develop GEP-44, a novel compound that addresses diabetes and weight loss similar to current market-leading GLP-1 drugs such as Ozempic. However, GEP-44 is specifically designed to overcome key limitations of existing therapies through a no-needle administration method and superior tolerability profile.
The compound aims to reduce the most commonly experienced side effects of leading in-market GLP-1 drugs, particularly nausea and gastrointestinal issues that often limit patient compliance and treatment continuation. GEP-44 functions as a triple antagonist and has demonstrated strong preclinical results according to the companies' announcement.
Transaction Structure and Financial Terms
The proposed transaction is structured as a share exchange through which SureNano will acquire 100% of GlucaPharm's issued and outstanding common shares. In exchange, GlucaPharm shareholders will receive an aggregate number of SureNano common shares, with the exact amount to be determined following completion of due diligence.
Following the transaction's completion, GlucaPharm shareholders are expected to collectively own under 20% of the issued and outstanding SureNano shares. The deal remains subject to several closing conditions, including completion of customary due diligence, negotiation and execution of a definitive agreement, and receipt of all required regulatory and third-party approvals.
Development Status and Market Positioning
GEP-44 currently has patents filed and academic validation completed, with market exploration underway. The companies position the compound as "poised to transform the treatment of obesity and diabetes worldwide" through its differentiated approach to GLP-1 therapy.
The needle-free administration method represents a significant potential advantage in patient acceptance and compliance, addressing a common barrier to GLP-1 therapy adoption. Combined with the improved tolerability profile, these features could provide competitive advantages in the crowded GLP-1 market.
Funding and Strategic Context
SureNano announced its intention on November 5, 2025, to complete a private placement for proceeds of up to $1.25 million through the sale of up to 10 million units at $0.125 per unit. Each unit comprises one common share and one warrant exercisable at $0.35 per share for 24 months.
The company intends to use private placement proceeds for operating expenses, legal and audit fees, general working capital, and expenses related to exploring new markets for its SureNano surfactant technology, as well as investigating complementary industries including the GlucaPharm opportunity.
SureNano's primary business involves the sale and distribution of SureNano surfactant, a food-grade compound for high-performance nanoemulsions. The company holds exclusive distribution rights within Canada, Oklahoma, and Colorado for this technology.
The negotiations to acquire GlucaPharm and the private placement are not interdependent, according to the company's announcement. There can be no guarantees that the proposed transaction will be completed as contemplated or at all, with finder's fees potentially payable in accordance with Canadian Securities Exchange policies.
